Haplotype of N-acetyltransferase 1 and 2 and risk of pancreatic cancer

Cancer Epidemiology Biomarkers and Prevention

Volumn 16, Issue 11, 2007, Pages 2379-2386

  Jiao, Li ^a   Doll, Mark A ^c   Hein, David W ^c   Bondy, Melissa L ^a   Hassan, Manal M ^a   Hixson, James E ^b   Abbruzzese, James L ^a   Li, Donghui ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b UNIVERSITY OF TEXAS SCHOOL OF PUBLIC HEALTH   (United States)

^c UNIVERSITY OF LOUISVILLE SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACYLTRANSFERASE; ARYLAMINE ACETYLTRANSFERASE;

ADOLESCENT; ADULT; AGED; ALGORITHM; ALLELE; ARTICLE; CANCER EPIDEMIOLOGY; CANCER RISK; CAUCASIAN; COMPARATIVE STUDY; CONFIDENCE INTERVAL; CONTROLLED STUDY; COVARIANCE; DIABETES MELLITUS; DIABETIC PATIENT; DISEASE ASSOCIATION; ENVIRONMENTAL EXPOSURE; GENETIC EPIDEMIOLOGY; GENETIC RISK; GENETIC VARIABILITY; GENOTYPE; HAPLOTYPE; HIGH RISK POPULATION; HUMAN; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; PANCREAS CANCER; PREVALENCE; PRIORITY JOURNAL; RISK ASSESSMENT; SEX RATIO; SINGLE NUCLEOTIDE POLYMORPHISM; SMOKING;

ADULT; ARYLAMINE N-ACETYLTRANSFERASE; FEMALE; GENOTYPE; HAPLOTYPES; HUMANS; ISOENZYMES; MALE; PANCREATIC NEOPLASMS; POLYMORPHISM, SINGLE NUCLEOTIDE; RISK FACTORS;

EID: 38849128680     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-06-0992     Document Type: Article

References (44)

1. Vineis P, Alavanja M, Buffler P, et al. Tobacco and cancer: recent epidemiological evidence. J Natl Cancer Inst 2004;96:99-106.
2. Anderson KE, Sinha R, Kulldorff M, et al. Meat intake and cooking techniques: associations with pancreatic cancer. Mutat Res 2002;506-7:225-31.
3. Manabe S, Tohyama K, Wada O, Aramaki T. Detection of a carcinogen, 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP), in cigarette smoke condensate. Carcinogenesis 1991;12:1945-7.
4. Turesky RJ. The role of genetic polymorphisms in metabolism of carcinogenic heterocyclic aromatic amines. Curr Drug Metab 2004;5:169-80.
5. Layton DW, Bogen KT, Knize MG, Hatch FT, Johnson VM, Felton JS. Cancer risk of heterocyclic amines in cooked foods: an analysis and implications for research. Carcinogenesis 1995;16:39-52.
6. Hein DW, Doll MA, Rustan TD, et al. Metabolic activation and deactivation of arylamine carcinogens by recombinant human NAT1 and polymorphic NAT2 acetyltransferases. Carcinogenesis 1993;14:1633-8.
7. Hirvonen A. Polymorphic NATs and cancer predisposition. IARC Sci Publ 1999;148:251-70.
8. Hickman D, Risch A, Buckle V, et al. Chromosomal localization of human genes for arylamine N-acetyltransferase. Biochem J 1994;297:441-5.
9. Matas N, Thygesen P, Stacey M, Risch A, Sim E. Mapping AAC1, AAC2 and AACP, the genes for arylamine N-acetyltransferases, carcinogen metabolising enzymes on human chromosome 8p22, a region frequently deleted in tumours. Cytogenet Cell Genet 1997;77:290-5.
10. Vatsis KP, Weber WW, Bell DA, et al. Nomenclature for N-acetyltransferases. Pharmacogenetics 1995;5:1-17.
11. Hein DW. N-acetyltransferase 2 genetic polymorphism: effects of carcinogen and haplotype on urinary bladder cancer risk. Oncogene 2006;25:1649-58.
12. Hein DW, Doll MA, Fretland AJ, et al. Molecular genetics and epidemiology of the NAT1 and NAT2 acetylation polymorphisms. Cancer Epidemiol Biomarkers Prev 2000;9:29-42.
13. Fretland AJ, Doll MA, Zhu Y, Smith L, Leff MA, Hein DW. Effect of nucleotide substitutions in N-acetyltransferase-1 on N-acetylation (deactivation) and O-acetylation (activation) of arylamine carcinogens: implications for cancer predisposition. Cancer Detect Prev 2002;26:10-4.
14. Zang Y, Zhao S, Doll MA, States JC, Hein DW. The T341C (Ile114Thr) polymorphism of N-acetyltransferase 2 yields slow acetylator phenotype by enhanced protein degradation. Pharmacogenetics 2004;14:717-23.
15. Gross M, Kruisselbrink T, Anderson K, et al. Distribution and concordance of N-acetyltransferase genotype and phenotype in an American population. Cancer Epidemiol Biomarkers Prev 1999;8:683-92.
16. Anderson KE, Hammons GJ, Kadlubar FF, et al. Metabolic activation of aromatic amines by human pancreas. Carcinogenesis 1997;18:1085-92.
17. Li D, Jiao L, Li Y, et al. Polymorphisms of cytochrome P4501A2 and N-acetyltransferase genes, smoking, and risk of pancreatic cancer. Carcinogenesis 2006;27:103-11.
18. Doll MA, Hein DW. Rapid genotype method to distinguish frequent and/or functional polymorphisms in human N-acetyltransferase-1. Anal Biochem 2002;301:328-32.
19. Doll MA, Hein DW. Comprehensive human NAT2 genotype method using single nucleotide polymorphism-specific polymerase chain reaction primers and fluorogenic probes. Anal Biochem 2001;288:106-8.
20. Stephens M, Smith NJ, Donnelly P. A new statistical method for haplotype reconstruction from population data. Am J Hum Genet 2001;68:978-89.
21. Sabbagh A, Darlu P. Inferring haplotypes at the NAT2 locus: the computational approach. BMC Genet 2005;6:30.
22. Zheng W, Deitz AC, Campbell DR, et al. N-acetyltransferase 1 genetic polymorphism, cigarette smoking, well-done meat intake, and breast cancer risk. Cancer Epidemiol Biomarkers Prev 1999;8:233-9.
23. Cascorbi I, Brockmoller J, Bauer S, Reum T, Roots I. NAT2*12A (803A→G) codes for rapid arylamine n-acetylation in humans. Pharmacogenetics 1996;6:257-9.
24. Wacholder S, Chanock S, Garcia-Closas M, El Ghormli L, Rothman N. Assessing the probability that a positive report is false: an approach for molecular epidemiology studies. J Natl Cancer Inst 2004;96:434-42.
25. Bruhn C, Brockmoller J, Cascorbi I, Roots I, Borchert HH. Correlation between genotype and phenotype of the human arylamine N-acetyltransferase type 1 (NAT1). Biochem Pharmacol 1999;58:1759-64.
26. de Leon JH, Vatsis KP, Weber WW. Characterization of naturally occurring and recombinant human N-acetyltransferase variants encoded by NAT1. Mol Pharmacol 2000;58:288-99.
27. Hein DW, Fretland AJ, Doll MA. Effects of single nucleotide polymorphisms in human N-acetyltransferase 2 on metabolic activation (O-acetylation) of heterocyclic amine carcinogens. Int J Cancer 2006;119:1208-11.
28. Bell DA, Badawi AF, Lang NP, Ilett KF, Kadlubar FF, Hirvonen A. Polymorphism in the N-acetyltransferase 1 (NAT1) polyadenylation signal: association of NAT1*10 allele with higher N-acetylation activity in bladder and colon tissue. Cancer Res 1995;55:5226-9.
29. Badawi AF, Hirvonen A, Bell DA, Lang NP, Kadlubar FF. Role of aromatic amine acetyltransferases, NAT1 and NAT2, in carcinogen-DNA adduct formation in the human urinary bladder. Cancer Res 1995;55:5230-7.
30. Risch A, Wallace DM, Bathers S, Sim E. Slow N-acetylation genotype is a susceptibility factor in occupational and smoking related bladder cancer. Hum Mol Genet 1995;4:231-6.
31. Millikan RC, Pittman GS, Newman B, et al. Cigarette smoking, N-acetyltransferases 1 and 2, and breast cancer risk. Cancer Epidemiol Biomarkers Prev 1998;7:371-8.
32. Doll MA, Jiang W, Deitz AC, Rustan TD, Hein DW. Identification of a novel allele at the human NAT1 acetyltransferase locus. Biochem Biophys Res Commun 1997;233:584-91.
33. Cascorbi I, Drakoulis N, Brockmoller J, Maurer A, Sperling K, Roots I. Arylamine N-acetyltransferase (NAT2) mutations and their allelic linkage in unrelated Caucasian individuals: correlation with phenotypic activity. Am J Hum Genet 1995;57:581-92.
34. Kadlubar FF, Anderson KE, Haussermann S, et al. Comparison of DNA adduct levels associated with oxidative stress in human pancreas. Mutat Res 1998;405:125-33.
35. Thompson PA, Seyedi F, Lang NP, et al. Comparison of DNA adduct levels associated with exogenous and endogenous exposures in human pancreas in relation to metabolic genotype. Mutat Res 1999;424:263-74.
36. Li D, Firozi PF, Zhang W, et al. DNA adducts, genetic polymorphisms, and K-ras mutation in human pancreatic cancer. Mutat Res 2002;513:37-48.
37. Yalin S, Hatungil R, Tamer L, et al. N-acetyltransferase 2 polymorphism in patients with diabetes mellitus. Cell Biochem Funct 2007;25:407-11.
38. Hegele RA, Kwan K, Harris SB, Hanley AJ, Zinman B, Cao H. NAT2 polymorphism associated with plasma glucose concentration in Canadian Oji-Cree. Pharmacogenetics 2000;10:233-8.
39. Zang Y, Doll MA, Zhao S, States JC, Hein DW. Functional characterization of single nucleotide polymorphisms and haplotypes of human N-acetyltransferase 2. Carcinogenesis 2007;28:1665-71.
40. Neugebauer S, Baba T, Watanabe T, Ishizaki T, Kurokawa K. The N-acetyltransferase (NAT) gene: an early risk marker for diabetic nephropathy in Japanese type 2 diabetic patients? Diabet Med 1994;11:783-8.
41. Deitz AC, Rothman N, Rebbeck TR, et al. Impact of misclassification in genotype-exposure interaction studies: example of N-acetyltransferase 2 (NAT2), smoking, and bladder cancer. Cancer Epidemiol Biomarkers Prev 2004;13:1543-6.
42. Rothman N, Stewart WF, Caporaso NE, Hayes RB. Misclassification of genetic susceptibility biomarkers: implications for case-control studies and cross-population comparisons. Cancer Epidemiol Biomarkers Prev 1993;2:299-303.
43. Upton A, Johnson N, Sandy J, Sim E. Arylamine N-acetyltransferases - of mice, men and microorganisms. Trends Pharmacol Sci 2001;22:140-6.
44. Bhatti P, Sigurdson AJ, Wang SS, et al. Genetic variation and willingness to participate in epidemiologic research: data from three studies. Cancer Epidemiol Biomarkers Prev 2005;14:2449-53.